Biosurgery Market Analysis, Size, Growth and Forecast to 2023

The global biosurgery market is witnessing considerable growth due to increasing geriatric population, increasing healthcare expenditure and growing sports related injuries. Moreover, growing prevalence of chronic diseases including cancer, cardiovascular disease, infectious diseases, autoimmune diseases, diabetes mellitus, and nephrological diseases is supporting the growth of the market. Based on product type, the surgical sealants segment is expected to grow at the fastest rate during the forecast period. The increasing adoption of biosurgery products across the globe, owing to its ease of use, and its efficacy in blood loss management is driving the growth of this segment.

Explore Report at: https://www.psmarketresearch.com/market-analysis/biosurgery-market

The rapid growth in emerging economies is expected to create opportunities for the manufacturers of biosurgery products. However, high cost of these products and lack of reimbursement are the key factors hampering the growth of the global market.

Cancer is a serious health concern across the globe. The increasing prevalence of cancer is driving the growth of the biosurgery market globally. According to the International Agency for Research on Cancer (IARC), a specialized cancer agency of WHO that promotes cancer research, as many as 12.7 million new patients were detected with cancer in 2008 globally and the number is expected to reach 21.4 million by 2030. Further, a total of 8.2 million deaths took place globally due to cancer in 2012, of which 1.6 million deaths were due to lung cancer, while 745,000 deaths were due to liver cancer, and 400,000 deaths were a result of oesophageal cancer.

Request For Table of Content at: https://www.psmarketresearch.com/market-analysis/biosurgery-market/toc-sample

The key players operating in the global biosurgery market are Baxter International Inc., C.R. Bard, Inc., Medtronic, Inc., Johnson & Johnson, Sanofi Group, B. Braun Melsungen AG, Cryolife, Stryker Corporation and Hemostasis, LLC.

Ambulatory EHR Market Trends, Analysis, Growth and Forecast to 2023

Ambulatory electronic health record (EHR) refers to a record that is maintained electronically in order to store the patient's medical records, which includes information about all surgeries and medical care that does not involves the need for the patient being admitted to a hospital or that are given in non-hospital settings such as urgent care clinics, physicians’ offices and at-home medical care. Health care providers can easily share information using this type of record. Ambulatory EHRs are stored in electronic databases that are accessible to doctors and other medical professionals which allows a physician to view a patient’s complete and accurate medical history. The global ambulatory EHR market is expected to grow in the future due to several advantages of EHRs over conventional health record systems such as the easy accessibility to the patient’s records.

Explore Report at: https://www.psmarketresearch.com/market-analysis/ehr-market

The ambulatory EHR market is segmented on the basis of delivery mode, practice size, application, end user, and region. The applications of ambulatory EHR include practice management, patient management, e-prescribing, referral management, population health management, decision support, and health analytics.

The major factors driving the growth of global ambulatory EHR market include the support from government for the adoption of health care intranet technologies (HCIT), the increase in the use of EHR solutions and need to reduce the overall healthcare cost. According to Centre for Disease Control and Prevention (CDC), in 2014 74.1% of office based physicians installed a certified electronic health record (EHR) system, as compared to 67.5%, in 2013. Also, more than one-third of physicians 39.1% approximately were sharing patient’s health information electronically with other ambulatory hospitals and providers. Additionally, according to data published by Office of the National Coordinator for Health IT analysis, an organization that implements the use of the advanced health information technology and the electronic exchange of health information, launched a Medicare EHR Incentive Program in which 684 health IT developers were supplying certified health IT to 354,395 ambulatory primary care physicians, podiatrists, optometrists, chiropractors, dentists and others participating in the Medicare EHR Incentive Program, as of July 2017.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/ehr-market/report-sample

In April 2016, eMDs, a provider of ambulatory EHR practice management (PM) software, revenue cycle management (RCM) solutions, and credentialing services, acquired several software technology assets from McKesson Business Performance Services (McKesson). The acquired McKesson assets included Practice Choice, Medisoft, Medisoft Clinical, Lytec, Lytec MD, and Practice Partner.

Some of the other key players in the global ambulatory EHR market include GE Healthcare, Cerner Corporation, eClinicalWorks, Epic Systems Corporation, McKesson Corporation, Quality Systems, Inc., Inc., Allscripts Healthcare Solutions, Inc., and Greenway Health, LLC.

Healthcare EDI Market Analysis, Size, Growth and Forecast to 2023

Healthcare electronic data interchange (EDI) facilitates the exchange of healthcare data which is processed using computer software in a standardized format. Healthcare industry processes a large number of documents such as medical records of patients, healthcare claims, and reimbursement records. Healthcare EDI helps in the exchange of this information among healthcare institutions, healthcare professionals, and patients. The use of healthcare EDI increases accuracy, improves productivity, helps in faster identification of errors, consumes less time, secures exchange of information and leads to ease of work for the healthcare providers, healthcare payers, and pharmacies. Healthcare EDI finds application in insurance and reimbursement data management, clinical trials and regulatory data management, and medical and dental patient database management. They key players such as Dell Technologies Inc. are prompting the growth of the global healthcare EDI market. In February 2017, Dell Technologies Inc. quickened the digital transformation in healthcare EDI market with the introduction of cloud integration solution for healthcare EDI.

Explore Report at: https://www.psmarketresearch.com/market-analysis/healthcare-edi-market

Global healthcare EDI market is expected to grow significantly during the forecast period. Some of the major factors driving growth of the market include expanding base of patient due to the increasing prevalence of chronic diseases, rising need to curtail healthcare costs, and government support for healthcare EDI. According to the World Health Organization (WHO), chronic disease is the leading cause of mortality globally, comprising 60% of all deaths. Also, approximately 17.7 million people died from cardiovascular diseases in 2015, representing 31% of all global deaths. Of these deaths, an approximate of 7.4 million deaths were due to coronary heart disease and 6.7 million were due to stroke. WHO also reported that globally 8.8 million people died from cancer which is 1 in 6 of all global deaths in 2015. With the rise in these chronic diseases, the volume of patient is also increasing. Moreover, these large number of deaths also prompts the end users to avail healthcare EDI products for different reimbursements claims.

Some of the key players in the global healthcare EDI market are GE Healthcare, Cognizant Technology Corporation, Cerner Corporation, Axway Software SA, Dell Technologies Inc., Synnex Corporation, McKesson Corporation, Allscripts Healthcare Solutions Inc., SSI Group, LLC, Comarch SA, Optum Inc., and Quality Systems Inc.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/healthcare-edi-market/report-sample

With respect to strategic developments, various new product launches and strategic alliances have been taking place in the healthcare EID market.

In April 2017, McKesson Corporation completed the acquisition of CoverMyMeds. CoverMyMeds’ software suite can automate the medication the medication prior to the authorizing process for more than 49,000 pharmacies, 500 electronic health records system, and 700,000 providers.

Cardiovascular Information System Market Analysis, Size, Growth, 2023

The global cardiovascular information system market is witnessing significant growth due to increasing prevalence of cardiovascular diseases, growing government initiates towards electronic health record system implementation and growing rate of medication errors. The remote access to data and images, and reduced IT burden in the diagnostic center and hospitals are supporting the demand of CVIS. Moreover, better interoperability and increasing healthcare cost are further expected to boost the market. Based on mode of operation, web-based segment leads the global market in terms of size, owing to high rate of awareness, improved interoperability, reduced IT burden in hospitals and relatively less cost. Based on component, the market for service segment is expected to grow at the fastest rate during the forecast period, due to upgradation of services for the complex software introduction and requirement for extensive training.

Explore Report at: https://www.psmarketresearch.com/market-analysis/cardiovascular-information-system-market

The increasing demand for cloud based solutions is expected to create opportunities for the players in the market. The unexplored market in developing economies is also creating abundant opportunities for the cardiovascular information system market to grow at a significant rate in the coming years. However, high cost of cardiovascular information, lack of standard healthcare protocol towards implementation of CVIS solution in developing countries and reluctance of healthcare provides to implement cardiovascular information system are the key factors hampering the growth of the global market.

The increasing female aging population is propelling the growth of the global Hysteroscope market. As reported by UN DESA (United Nation Department of Economic and Social Affairs) in the year 2013, the elder population is predominantly female. As women tend to live longer than men, while older women have outnumbered older men almost everywhere in the world. It further reported that in the year 2013, globally, there were 85 men per 100 women in the age group 60 years or plus; and 61 men per 100 women in the age group 80 years or plus. The elderly population is more susceptible to gynaecological problems, such as abnormal uterine bleeding, fibroids, and polyps, as compared to adults, which is fuelling the demand of the global hysteroscope market. Aging in females leads to changes in hormones leading to irregular menses, which contributes to the demand for Geographically, North America has been the largest market for cardiovascular information system, owing to increasing incidence of cardiovascular disease, well established healthcare infrastructure, and strict privacy and security regulation in the region. The U.S. contributed largest revenue to the North American as well as global cardiovascular information system market. The increase in integration of the electronic health record maintenance system and favorable government policies are driving the growth of the U.S. cardiovascular information system. Globally, the cardiovascular information system market is expected to witness the fastest growth in Asia-Pacific during the forecast period. The highest growth in the region is attributed to large pool of patient, improving healthcare infrastructure, increasing incidence of cardiovascular disease, and growing medical tourism in the region.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/cardiovascular-information-system-market/report-sample

The key players operating in the global cardiovascular information system market are Philips Healthcare, McKesson Corporation, Philips Healthcare, General Electric Company, Siemens AG, AGFA Healthcare and Cerner Corporation.

Anesthesia Monitoring Devices Market Analysis, Size, Forecast to 2023

The global anesthesia monitoring device market is witnessing substantial growth due to advancement in technology of anesthesia monitoring device and increasing number of surgeries. Growing awareness among physicians about various factors such as appropriate route of administration, right dose of anesthetic drug and choice of anesthetic drug, is further expected to boost the market. Based on product type, advanced anesthesia monitor was globally the largest segment due to its accuracy, durability and reliability in monitoring anesthesia. It also helps in monitoring vital parameters such as oxygen saturation level, heart rate, blood pressure, and carbon dioxide levels. Hospitals have been the largest user of anesthesia monitoring devices due to availability of advanced healthcare infrastructure, and presence of skilled professionals in the hospital.

Explore Report at: https://www.psmarketresearch.com/market-analysis/anesthesia-monitoring-device-market

Rapidly growing geriatric population is also expected to be a growth factor for the anesthesia monitoring device market, as geriatric population has weakened body functions and require proper monitoring during the surgery. As per the United Nations Department of Economic and Social Affairs (UN-DESA) report on the global aging population, the population of people aged 60 years or above is growing with high rate. The global percentage of people aged 60 or above in 2013 was 11.7% and it is expected to reach 21.1% by the end of 2050. Further, the number of people aged 60 years and above is expected to reach approximately 437 million in China, 324 million in India, 107 million in the U.S. and 58 million in Brazil by 2050.

The increasing female aging population is propelling the growth of the global Hysteroscope market. As reported by UN DESA (United Nation Department of Economic and Social Affairs) in the year 2013, the elder population is predominantly female. As women tend to live longer than men, while older women have outnumbered older men almost everywhere in the world. It further reported that in the year 2013, globally, there were 85 men per 100 women in the age group 60 years or plus; and 61 men per 100 women in the age group 80 years or plus. The elderly population is more susceptible to gynaecological problems, such as abnormal uterine bleeding, fibroids, and polyps, as compared to adults, which is fuelling the demand of the global hysteroscope market. Aging in females leads to changes in hormones leading to irregular menses, which contributes to the demand for Geographically, North America has been the largest market for anesthesia monitoring device, owing to increasing awareness of patient safety and awareness among patient and physicians, favorable reimbursement network, and favorable government funding in the region. The U.S. contributed largest revenue to the North American as well as global anesthesia monitoring device market. Globally, the anesthesia monitoring device market is expected to witness the fastest growth in Asia-Pacific during the forecast period. The highest growth in the region is attributed to growing geriatric population, large pool of patients, advancing healthcare system, and increasing number of surgeries in the region.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/anesthesia-monitoring-device-market/report-sample

The key players operating in the global market are Medtronic Plc, General Electric Company, Philips Healthcare, Masimo Corporation, Nihon Kohden Corporation, Dragerwerk AG & Co. KGaA, Schiller AG and Mindray Medical International Limited.

AKT/Protein Kinase B Inhibitors Pipeline - Clinical Trials and Designation

The AKT inhibitors pipeline has more than 15 drugs. In pipeline analysis, drugs are analyzed based on route of administration and molecule type. The pipeline is also analyzed on the basis of monotherapy and combination therapy, and different clinical phases including Phase III, Phase II, Phase I and Pre-clinical stage.

Explore Report at: https://www.psmarketresearch.com/market-analysis/akt-protein-kinase-b-inhibitors-pipeline-analysis

Phase III & Filed

Phase III clinical trial known for the comparison of new treatments with the standard treatment in which the safety, efficacy and side effects of new intervention is compared with the already existing treatment. The Phase III clinical trial takes around 2-3 years to complete and the total number of participants vary from 100-1,000. After the completion of Phase III stage, the company files New Drug Application (NDA) to the regulatory authorities known as filed stage. There is no AKT inhibitor drug in Phase III clinical trial and one drug is in filed stage. Novartis AG has filed NDA in U.S. for midostaurin, for the treatment of FLT3-mutated acute myeloid leukemia. The marketing authorization application has already been accepted by the European Medicines Agency for midostaurin for the treatment of FLT3-mutated acute myeloid leukemia.

Phase II

Rexahn Pharmaceuticals, Inc. has developed Archexin, a phase II drug candidate for the treatment of renal cell carcinoma. Phase II clinical trial is the second phase that answer safety, efficacy and dosing of the new intervention. There are total 8 drugs present in phase II trial of AKT inhibitors. Phase II clinical trial take around 2 years to complete and between 100 – 120 patients participate in the Phase II trial.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/akt-protein-kinase-b-inhibitors-pipeline-analysis/report-sample

Phase I

Triciribine phosphate (PTX 200), a drug candidate of Prescient Therapeutics Ltd., is in phase I stage of development for the treatment of acute myeloid leukemia, recurrent or persistent platinum resistant ovarian cancer, breast cancer, lung cancer and esophageal cancer. There are 4 drugs present in Phase I clinical stage. In Phase I clinical trial, safety of the new intervention is determined. The trial takes around 1-2 years to complete and the total number of volunteers participating in the trial vary between 15 – 30.

Pipeline analysis provides description about the key companies which are developing AKT inhibitor drugs. Some of the key players actively involved in the research and development are AstraZeneca plc, Cellectar Biosciences Inc., GlaxoSmithKline plc, Novartis AG, Prescient Therapeutics Ltd and Asana BioSciences, LLC.

Fungal Infections Pipeline Analysis - Designation, Collaboration and Other Developments

The fungal infection pipeline has more than 60 drugs. In pipeline analysis, drugs are analyzed based on route of administration and molecule type. The pipeline is also analyzed on the basis of monotherapy and combination therapy, and different clinical phases including Phase III, Phase II, Phase I and Pre-clinical stage.

Explore Report at: https://www.psmarketresearch.com/market-analysis/fungal-infections-pipeline-analysis

Phase III & Filed

Phase III clinical trial known for the comparison of new treatments with the standard treatment in which the safety, efficacy and side effects of new intervention is compared with the already existing treatment. The Phase III clinical trial takes around 2-3 years to complete and the total number of participants vary from 100-1,000. After the completion of Phase III stage, the company filed New Drug Application to the regulatory authorities known as filed stage. There are 3 drugs for fungal infection in Phase III clinical trial. Terbinafine, also known as MOB-015, is a drug candidate of Moberg Pharma AB. The drug candidate is being developed for the treatment of onychomycosis. In fungal infection, no drugs have been registered for NDA filing.

Phase II

VT-1161, a phase II drug candidate of Viamet Pharmaceuticals, Inc. for the treatment of onychomycosis (Fungal Infection) and recurrent vulvovaginal candidiasis. Phase II clinical trial is the second phase that answer safety, efficacy and dosing of the new intervention. There are total 14 drugs present in phase II trial of fungal infections. Phase II clinical trial take around 2 years to complete and between 100 – 120 patients participate in the Phase II trial.

Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/fungal-infections-pipeline-analysis/report-sample

Phase I

PC945 is under development by Pulmocide Ltd. for the prevention and treatment for aspergillosis in cystic fibrosis, lung transplant and allergic bronchopulmonary aspergillosis. The drug candidate targets the cytochrome P450 C-14 alpha demethylase (CYP51) and inhibits its action. There are 8 drugs present in Phase I clinical stage. In Phase I clinical trial, safety of the new intervention is determined. The trial takes around 1-2 years to complete and the total number of volunteers participating in the trial vary between 15 – 30.

Pipeline analysis provides description about the key companies developing fungal infections drugs. Some of the key players actively involved in the research and development are Moberg Pharma AB, Viamet Pharmaceuticals, Inc., Pulmocide Ltd., Vyom Biosciences, NovaDigm Therapeutics Inc., Matinas BioPharma Holdings Inc., Sol-Gel Technologies Ltd. and Eisai Co. Ltd.